Supply Chain

Taking cues from launches so far in oncology and rheumatology, three important considerations for biosimilar marketability are outlined

The new parent company will expand security, monitoring and remedial action for pharma shipments

Parties will collaborate in enhancing chronic disease care therapies

Building a data-sharing system for the US Drug Supply Chain Security Act (DSCSA) is two years from a mandated completion—will industry be ready?

Firms will merge under the CSafe brand, allowing for delivery of temperature-sensitive items

ABC’s new acquisition, FirstView Financial, addresses underpayment of pharmacies, as well as patient assistance programs

Pharma firms—not only in Europe but in the US as well—are continuously looking for alternative supply channels inside their respective blocks

Deal expands pharma giant’s influence in inflammation and immunology markets

Includes 20 million more doses by the end of the 2021

The $17.4-billion deal, CDMO says, will help expand its offerings in the clinical development space

Survey draws attention to the need for improving issues surrounding supply chain visibility

Site is located in the state of Gujarat, a major hub for pharma logistics

Collaboration focuses on continuing to improve time to therapy and medication adherence for patients, while effectively optimizing clinical data

CDMO’s financial commitment will feature construction of a new GMP clinical trial development facility

Latest report indicates that air cargo demand is outperforming pre-Covid stats from 2019

Five-year deal covers manufacturing of molecules, ranging from monoclonal antibodies to antibody-drug conjugates

Transaction is anticipated to further Novo’s research in the field of RNAi therapeutics

Approval is for the 50-µg dosage

Four trends shaping healthcare in 2022 and beyond

How AI-powered support automation can solve the data problem in clinical trial management

Ongoing strides in data mining, data analytics, modeling and simulation are opening up new and more definitive opportunities to apply data-driven insights to improve everything from upstream drug discovery and clinical trials, to the downstream go-to-market strategy and post-patent lifecycle management

Industrialized collaboration is critical to taking next-generation cell and gene therapies to the next level—if companies can build on pandemic-partnering momentum

PBM fees and vertical integration are also at the top of the list

Partnership further increases investment firm’s repertoire in healthcare space

Boston area facility will focus heavily on cold chain services